तुलना करने के लिए मीट्रिक्स | NMAD | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत औद्योगिक | संबंध संबंधNMADपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 0.0x | −3.7x | −0.4x | |
PEG अनुपात | 0.00 | 0.01 | 0.00 | |
क़ीमत/बुक | 0.0x | 1.5x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.0x | 64.4x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 0.0% | 179.0% | 50.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | −1.2% | 7.8% | अनलॉक करें |
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company’s LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.